Key takeaways
- Wegovy and Ozempic share semaglutide but are positioned differently in dosing and approved use.
- Routine fit depends on your prescribed goal, dose pathway, coverage, and tolerance pattern.
- Comparison guides help frame questions, but medication choice still belongs in a clinician conversation.
Quick answer
A plain-language comparison of weekly semaglutide options, including routine fit and key differences.
Wegovy and Ozempic both use semaglutide, but they are positioned differently in dosing, approved use, and everyday routine fit. The practical question is usually not whether they are related, but which label, schedule, and goal match the plan you are actually following.
What is the difference between Wegovy and Ozempic?
Although both medications contain semaglutide and work the same way in the body, they are prescribed for different conditions and at different doses. Ozempic was FDA-approved in 2017 for improving blood sugar control in adults with type 2 diabetes. Wegovy received FDA approval in 2021 specifically for chronic weight management in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related condition.
In March 2024, the FDA expanded Wegovy's label to include cardiovascular risk reduction — making it the first weight-management drug approved to lower the risk of heart attack, stroke, and cardiovascular death in adults with established heart disease and obesity or overweight. This approval was based on the landmark SELECT trial.
How do the dosing schedules compare?
Both medications are injected subcutaneously once per week and follow a gradual dose-escalation schedule to minimize gastrointestinal side effects. However, Wegovy has a higher maximum dose and a longer titration period.
| Detail | Ozempic | Wegovy |
|---|---|---|
| Starting dose | 0.25 mg/week | 0.25 mg/week |
| Titration steps | 0.25 → 0.5 → 1 → 2 mg | 0.25 → 0.5 → 1 → 1.7 → 2.4 mg |
| Time to maintenance dose | ~8 weeks (0.5 mg) or ~12 weeks (1 mg) | ~16 weeks (2.4 mg) |
| Maximum dose | 2 mg/week | 2.4 mg/week |
| Dose increase interval | Every 4 weeks | Every 4 weeks |
Wegovy includes an extra titration step at 1.7 mg that Ozempic does not have, which helps patients adjust before reaching the higher 2.4 mg maintenance dose. For a detailed breakdown of the Ozempic titration timeline, see our Ozempic injection schedule guide.
Which one leads to more weight loss?
Both medications produce significant weight loss, but Wegovy generally leads to greater reductions because it is prescribed at a higher dose. In the STEP 1 clinical trial, adults with obesity or overweight who took Wegovy 2.4 mg lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo. Approximately 86% of participants on Wegovy lost at least 5% of their body weight, and about 50% lost 15% or more.
In the longer-term STEP 5 trial, weight loss was sustained at an average of 15.2% over 104 weeks (2 years) with Wegovy 2.4 mg.
For Ozempic, the SUSTAIN clinical trials focused on patients with type 2 diabetes. In the SUSTAIN FORTE trial, patients on Ozempic 2 mg lost an average of 6.9 kg (approximately 7–8% body weight) at 40 weeks. In SUSTAIN 1, semaglutide 1 mg produced an average weight loss of 4.53 kg over 30 weeks.
The difference in weight loss largely reflects the dose gap: Wegovy's 2.4 mg maintenance dose is 20% higher than Ozempic's maximum 2 mg dose.
What does the research say about cardiovascular benefits?
The SELECT trial — a randomized, double-blind study of 17,604 adults aged 45 and older with overweight or obesity and established cardiovascular disease (but without diabetes) — found that Wegovy 2.4 mg reduced the risk of major adverse cardiovascular events by 20% compared to placebo. Specifically, the trial showed a 28% reduction in heart attacks, a 7% decrease in non-fatal strokes, and a 15% drop in cardiovascular-related deaths.
Notably, the cardiovascular benefits appeared within 3 months of starting treatment, before significant weight loss had occurred. This suggests semaglutide may have heart-protective effects beyond weight reduction.
Ozempic also has cardiovascular data. In the SUSTAIN 6 trial, Ozempic reduced major cardiovascular events by 26% in patients with type 2 diabetes and high cardiovascular risk. However, Ozempic's FDA label for cardiovascular benefit is specific to patients with type 2 diabetes and chronic kidney disease, not for weight management.
How do side effects compare?
Because both medications contain semaglutide, they share the same side-effect profile. The most common adverse effects are gastrointestinal and tend to occur during dose escalation. However, side effects may be more frequent with Wegovy because of its higher maximum dose.
| Side effect | Ozempic (SUSTAIN trials) | Wegovy (STEP trials) |
|---|---|---|
| Nausea | ~20% | ~44% |
| Diarrhea | ~9% | ~30% |
| Vomiting | ~9% | ~25% |
| Constipation | ~5% | ~24% |
| Abdominal pain | ~6% | ~11% |
These side effects are typically mild to moderate and tend to improve over the first few weeks. The gradual dose-escalation schedule for both medications is specifically designed to reduce these symptoms. If gastrointestinal side effects are severe or persistent, a healthcare provider may recommend slowing the titration or staying at a lower dose for a longer period.
Both medications carry the same serious warnings, including a boxed warning about the risk of thyroid C-cell tumors (observed in rodent studies), pancreatitis, gallbladder problems, and potential kidney injury. Neither medication should be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
How much do Wegovy and Ozempic cost?
Without insurance, both medications are expensive. The list price for Wegovy is approximately $1,349 per month, and Ozempic costs close to $1,000 per month at retail price. With insurance coverage, the average out-of-pocket cost drops to roughly $331 per month, though some plans may cover the full cost.
Insurance coverage differs significantly between the two. Ozempic is more widely covered because it is prescribed for type 2 diabetes, a condition most insurance plans include in their formulary. Wegovy, as a weight-management medication, often requires prior authorization and may not be covered by all plans — though coverage has been expanding.
Novo Nordisk offers savings programs for both medications. New patients may qualify for introductory pricing of $199 per month for the first two lower doses, with a standard cash price of $349 per month thereafter. Starting in July 2026, Medicare's GLP-1 Bridge program is expected to cover Wegovy (but not Ozempic) for weight loss at a $50 monthly copay for eligible beneficiaries.
Can you switch between Wegovy and Ozempic?
Switching between Wegovy and Ozempic is possible because they contain the same active ingredient. However, any switch should be guided by a healthcare provider. Common reasons for switching include a change in treatment goals (for example, from diabetes management to weight loss, or vice versa), insurance coverage changes, or medication availability.
When switching, the provider will typically match the dose as closely as possible. For instance, a patient on Ozempic 1 mg might transition to Wegovy 1 mg and then continue titrating up to 1.7 mg and 2.4 mg. It is important not to take both medications at the same time, as they contain the same active ingredient and doubling up increases the risk of serious side effects.
How can you track your medication and progress?
Whether you're taking Wegovy or Ozempic, consistent tracking helps you stay on schedule and monitor your response to treatment. Key things to track include your current dose, injection day and site rotation, side effects during titration, and weight or other health metrics over time.
Glone is a free iOS app built specifically for GLP-1 medication tracking. It supports both Wegovy and Ozempic with features like injection reminders, smart site rotation, dose tracking through titration, and AI-powered food analysis — so you can focus on your health goals while the app keeps your schedule organized. If your current routine is Wegovy-specific, the Glone Wegovy tracker page gives a cleaner product overview for that weekly workflow.
Sources
- FDA Prescribing Information for Ozempic (semaglutide) injection — accessdata.fda.gov
- FDA Prescribing Information for Wegovy (semaglutide) injection — accessdata.fda.gov
- STEP 1 Trial — Wilding et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," NEJM 2021 — nejm.org
- STEP 5 Trial — Garvey et al., "Two-year effects of semaglutide in adults with overweight or obesity," Nature Medicine 2022 — nature.com
- SELECT Trial — Lincoff et al., "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes," NEJM 2023 — nejm.org
- SUSTAIN FORTE Trial — Frías et al., Lancet Diabetes & Endocrinology 2021 — pubmed.ncbi.nlm.nih.gov
- Semaglutide — StatPearls, NCBI Bookshelf — ncbi.nlm.nih.gov